San Diego Business Journal

San Diego-based Pfenex Inc., a clinical-stage biotechnology company that makes biosimilars, announced its fourth quarter financial results March 16, reporting a net loss of $3.57 million on revenue of $2.02 million. In the like quarter of 2013, the company reported $469,000 net loss on revenue of $4.23 million.

For 2014 as a whole, Pfenex reported a net loss of $9.79 million on revenue of $10.64 million. The company’s net loss for 2013 was $4.06 million on revenue of $11.91 million.